Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial
Background CAVE is a single arm, Phase 2 trial, that demonstrated anti-tumor activity of cetuximab rechallenge plus avelumab in patients with RAS wild type (wt) metastatic colorectal cancer (mCRC). Objective We conducted a post hoc analysis to identify potential radiomic biomarkers for patients with...
Gespeichert in:
| Veröffentlicht in: | Clinical drug investigation 2024-07, Vol.44 (7), p.541-548 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 548 |
|---|---|
| container_issue | 7 |
| container_start_page | 541 |
| container_title | Clinical drug investigation |
| container_volume | 44 |
| creator | Martinelli, Erika Ciardiello, Davide Martini, Giulia Napolitano, Stefania Del Tufo, Sara D’Ambrosio, Luca De Chiara, Marco Famiglietti, Vincenzo Nacca, Valeria Cardone, Claudia Avallone, Antonio Cremolini, Chiara Pietrantonio, Filippo Maiello, Evaristo Granata, Vincenza Troiani, Teresa Cappabianca, Salvatore Ciardiello, Fortunato Nardone, Valerio Reginelli, Alfonso |
| description | Background
CAVE is a single arm, Phase 2 trial, that demonstrated anti-tumor activity of cetuximab rechallenge plus avelumab in patients with
RAS
wild type (wt) metastatic colorectal cancer (mCRC).
Objective
We conducted a post hoc analysis to identify potential radiomic biomarkers for patients with CRC liver metastasis (LM).
Patients and Methods
Patients with LM that could be measured by enhanced contrast phase computed tomography (CT) imaging at baseline and at first response evaluation were included. Multiple texture parameters were extracted with the LifeX Software. Delta-texture (D-TA) variations were calculated by comparing data at baseline and after treatment.
Results
Overall, 55/77 patients (71%) had LM; 39 met the inclusion criteria for the current analysis. The D-TA parameters that significantly correlated at univariate analysis with median progression-free survival (mPFS) were Entropy
Histogram
(
p
= 0.021), Homogeneity
GLCM
(
p
< 0.001) and Dissimilarity
GLCM
(
p
= 0.002). At multivariate analysis, only Homogeneity
GLCM
resulted significant for PFS (
p
= 0.001). Patients (19/39, 48.7%) with reduction of Homogeneity
GLCM
experienced better mPFS (4.6 vs 2.9 months; HR 0.45; 95% CI 0.23–0.88;
p
= 0.021) and median overall survival (mOS) (17.3 vs 6.8 months; HR 0.40, 95% CI 0.21–0.80;
p
= 0.010). A trend to better mPFS, was also observed in patients with
RAS/BRAF
wt circulating tumor DNA and reduction of Homogeneity
GLCM
. Overall survival was significantly better in this subgroup of patients with low Homogeneity
GLCM
: mOS was 17.8 (95% CI 15.5–20.2) versus 6.8 months (95% CI 3.6–10.0) (HR 0.34, 95% CI 0.14–0.81;
p
= 0.016).
Conclusion
Reduction in the D-TA parameter Homogeneity
GLCM
by radiomic analysis correlates with improved outcomes in patients with LM receiving cetuximab rechallenge plus avelumab therapy. Larger prospective studies are needed to validate and confirm these findings. |
| doi_str_mv | 10.1007/s40261-024-01372-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3070793549</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3086411415</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-b29f2bdb4290b304591737aec5f726709da4d4c31dec8a3337d3e36f5eee82583</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhS0EoqXwAiyQJTZsDP6Lk7CrommpNFWrUWFrOc5Nx1ViD7ZTxEvxjJiZASQWrHxlf-cc6x6EXjP6nlFaf0iScsUI5ZJQJmpO6BN0yljdEtay5ul-FoRXSpygFyk9UMoUU_w5OhFN0ygh1Cn6sTGDC7Oz-NZEM0OGmPAYIs5bwKtHMy0mu-BxGPEG0i74BDgHfBfB5Bl8xs7ja8gm5cJZ3IUpRLDZTLgz3kIsttkVLuFvLm_x2j2Wu6MgufQRXzg_OH9fQmOY96nd-ZcVuby5usZzt-nw7daUTF4inZleomejmRK8Op5n6PPF6q77RNY3l1fd-ZpYwVUmPW9H3g-95C3tBZVVWzZRG7DVWHNV03YwcpBWsAFsY4QQ9SBAqLECgIZXjThD7w6-uxi-LpCynl2yME3GQ1iSFrSmdSsq2Rb07T_oQ1iiL78rVKMkY5JVheIHysaQUoRR76KbTfyuGdW_2tSHNnVpU-_b1LSI3hytl36G4Y_kd30FEAcglSd_D_Fv9n9sfwLVGqqu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3086411415</pqid></control><display><type>article</type><title>Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Martinelli, Erika ; Ciardiello, Davide ; Martini, Giulia ; Napolitano, Stefania ; Del Tufo, Sara ; D’Ambrosio, Luca ; De Chiara, Marco ; Famiglietti, Vincenzo ; Nacca, Valeria ; Cardone, Claudia ; Avallone, Antonio ; Cremolini, Chiara ; Pietrantonio, Filippo ; Maiello, Evaristo ; Granata, Vincenza ; Troiani, Teresa ; Cappabianca, Salvatore ; Ciardiello, Fortunato ; Nardone, Valerio ; Reginelli, Alfonso</creator><creatorcontrib>Martinelli, Erika ; Ciardiello, Davide ; Martini, Giulia ; Napolitano, Stefania ; Del Tufo, Sara ; D’Ambrosio, Luca ; De Chiara, Marco ; Famiglietti, Vincenzo ; Nacca, Valeria ; Cardone, Claudia ; Avallone, Antonio ; Cremolini, Chiara ; Pietrantonio, Filippo ; Maiello, Evaristo ; Granata, Vincenza ; Troiani, Teresa ; Cappabianca, Salvatore ; Ciardiello, Fortunato ; Nardone, Valerio ; Reginelli, Alfonso</creatorcontrib><description>Background
CAVE is a single arm, Phase 2 trial, that demonstrated anti-tumor activity of cetuximab rechallenge plus avelumab in patients with
RAS
wild type (wt) metastatic colorectal cancer (mCRC).
Objective
We conducted a post hoc analysis to identify potential radiomic biomarkers for patients with CRC liver metastasis (LM).
Patients and Methods
Patients with LM that could be measured by enhanced contrast phase computed tomography (CT) imaging at baseline and at first response evaluation were included. Multiple texture parameters were extracted with the LifeX Software. Delta-texture (D-TA) variations were calculated by comparing data at baseline and after treatment.
Results
Overall, 55/77 patients (71%) had LM; 39 met the inclusion criteria for the current analysis. The D-TA parameters that significantly correlated at univariate analysis with median progression-free survival (mPFS) were Entropy
Histogram
(
p
= 0.021), Homogeneity
GLCM
(
p
< 0.001) and Dissimilarity
GLCM
(
p
= 0.002). At multivariate analysis, only Homogeneity
GLCM
resulted significant for PFS (
p
= 0.001). Patients (19/39, 48.7%) with reduction of Homogeneity
GLCM
experienced better mPFS (4.6 vs 2.9 months; HR 0.45; 95% CI 0.23–0.88;
p
= 0.021) and median overall survival (mOS) (17.3 vs 6.8 months; HR 0.40, 95% CI 0.21–0.80;
p
= 0.010). A trend to better mPFS, was also observed in patients with
RAS/BRAF
wt circulating tumor DNA and reduction of Homogeneity
GLCM
. Overall survival was significantly better in this subgroup of patients with low Homogeneity
GLCM
: mOS was 17.8 (95% CI 15.5–20.2) versus 6.8 months (95% CI 3.6–10.0) (HR 0.34, 95% CI 0.14–0.81;
p
= 0.016).
Conclusion
Reduction in the D-TA parameter Homogeneity
GLCM
by radiomic analysis correlates with improved outcomes in patients with LM receiving cetuximab rechallenge plus avelumab therapy. Larger prospective studies are needed to validate and confirm these findings.</description><identifier>ISSN: 1173-2563</identifier><identifier>ISSN: 1179-1918</identifier><identifier>EISSN: 1179-1918</identifier><identifier>DOI: 10.1007/s40261-024-01372-0</identifier><identifier>PMID: 38886336</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biomarkers ; Cancer therapies ; Cetuximab - administration & dosage ; Cetuximab - therapeutic use ; Colorectal cancer ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - pathology ; Datasets ; Female ; Humans ; Internal Medicine ; Liver ; Liver Neoplasms - diagnostic imaging ; Liver Neoplasms - drug therapy ; Liver Neoplasms - secondary ; Male ; Medical imaging ; Medical prognosis ; Medicine ; Medicine & Public Health ; Metastasis ; Middle Aged ; Multivariate analysis ; Oncology ; Patients ; Pharmacology/Toxicology ; Pharmacotherapy ; Progression-Free Survival ; Radiomics ; Regression analysis ; Short Communication ; Software ; Tomography ; Tomography, X-Ray Computed - methods</subject><ispartof>Clinical drug investigation, 2024-07, Vol.44 (7), p.541-548</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024</rights><rights>2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</rights><rights>Copyright Springer Nature B.V. Jul 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c326t-b29f2bdb4290b304591737aec5f726709da4d4c31dec8a3337d3e36f5eee82583</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40261-024-01372-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40261-024-01372-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38886336$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Martinelli, Erika</creatorcontrib><creatorcontrib>Ciardiello, Davide</creatorcontrib><creatorcontrib>Martini, Giulia</creatorcontrib><creatorcontrib>Napolitano, Stefania</creatorcontrib><creatorcontrib>Del Tufo, Sara</creatorcontrib><creatorcontrib>D’Ambrosio, Luca</creatorcontrib><creatorcontrib>De Chiara, Marco</creatorcontrib><creatorcontrib>Famiglietti, Vincenzo</creatorcontrib><creatorcontrib>Nacca, Valeria</creatorcontrib><creatorcontrib>Cardone, Claudia</creatorcontrib><creatorcontrib>Avallone, Antonio</creatorcontrib><creatorcontrib>Cremolini, Chiara</creatorcontrib><creatorcontrib>Pietrantonio, Filippo</creatorcontrib><creatorcontrib>Maiello, Evaristo</creatorcontrib><creatorcontrib>Granata, Vincenza</creatorcontrib><creatorcontrib>Troiani, Teresa</creatorcontrib><creatorcontrib>Cappabianca, Salvatore</creatorcontrib><creatorcontrib>Ciardiello, Fortunato</creatorcontrib><creatorcontrib>Nardone, Valerio</creatorcontrib><creatorcontrib>Reginelli, Alfonso</creatorcontrib><title>Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial</title><title>Clinical drug investigation</title><addtitle>Clin Drug Investig</addtitle><addtitle>Clin Drug Investig</addtitle><description>Background
CAVE is a single arm, Phase 2 trial, that demonstrated anti-tumor activity of cetuximab rechallenge plus avelumab in patients with
RAS
wild type (wt) metastatic colorectal cancer (mCRC).
Objective
We conducted a post hoc analysis to identify potential radiomic biomarkers for patients with CRC liver metastasis (LM).
Patients and Methods
Patients with LM that could be measured by enhanced contrast phase computed tomography (CT) imaging at baseline and at first response evaluation were included. Multiple texture parameters were extracted with the LifeX Software. Delta-texture (D-TA) variations were calculated by comparing data at baseline and after treatment.
Results
Overall, 55/77 patients (71%) had LM; 39 met the inclusion criteria for the current analysis. The D-TA parameters that significantly correlated at univariate analysis with median progression-free survival (mPFS) were Entropy
Histogram
(
p
= 0.021), Homogeneity
GLCM
(
p
< 0.001) and Dissimilarity
GLCM
(
p
= 0.002). At multivariate analysis, only Homogeneity
GLCM
resulted significant for PFS (
p
= 0.001). Patients (19/39, 48.7%) with reduction of Homogeneity
GLCM
experienced better mPFS (4.6 vs 2.9 months; HR 0.45; 95% CI 0.23–0.88;
p
= 0.021) and median overall survival (mOS) (17.3 vs 6.8 months; HR 0.40, 95% CI 0.21–0.80;
p
= 0.010). A trend to better mPFS, was also observed in patients with
RAS/BRAF
wt circulating tumor DNA and reduction of Homogeneity
GLCM
. Overall survival was significantly better in this subgroup of patients with low Homogeneity
GLCM
: mOS was 17.8 (95% CI 15.5–20.2) versus 6.8 months (95% CI 3.6–10.0) (HR 0.34, 95% CI 0.14–0.81;
p
= 0.016).
Conclusion
Reduction in the D-TA parameter Homogeneity
GLCM
by radiomic analysis correlates with improved outcomes in patients with LM receiving cetuximab rechallenge plus avelumab therapy. Larger prospective studies are needed to validate and confirm these findings.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biomarkers</subject><subject>Cancer therapies</subject><subject>Cetuximab - administration & dosage</subject><subject>Cetuximab - therapeutic use</subject><subject>Colorectal cancer</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Datasets</subject><subject>Female</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Liver</subject><subject>Liver Neoplasms - diagnostic imaging</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - secondary</subject><subject>Male</subject><subject>Medical imaging</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Multivariate analysis</subject><subject>Oncology</subject><subject>Patients</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacotherapy</subject><subject>Progression-Free Survival</subject><subject>Radiomics</subject><subject>Regression analysis</subject><subject>Short Communication</subject><subject>Software</subject><subject>Tomography</subject><subject>Tomography, X-Ray Computed - methods</subject><issn>1173-2563</issn><issn>1179-1918</issn><issn>1179-1918</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1u1DAUhS0EoqXwAiyQJTZsDP6Lk7CrommpNFWrUWFrOc5Nx1ViD7ZTxEvxjJiZASQWrHxlf-cc6x6EXjP6nlFaf0iScsUI5ZJQJmpO6BN0yljdEtay5ul-FoRXSpygFyk9UMoUU_w5OhFN0ygh1Cn6sTGDC7Oz-NZEM0OGmPAYIs5bwKtHMy0mu-BxGPEG0i74BDgHfBfB5Bl8xs7ja8gm5cJZ3IUpRLDZTLgz3kIsttkVLuFvLm_x2j2Wu6MgufQRXzg_OH9fQmOY96nd-ZcVuby5usZzt-nw7daUTF4inZleomejmRK8Op5n6PPF6q77RNY3l1fd-ZpYwVUmPW9H3g-95C3tBZVVWzZRG7DVWHNV03YwcpBWsAFsY4QQ9SBAqLECgIZXjThD7w6-uxi-LpCynl2yME3GQ1iSFrSmdSsq2Rb07T_oQ1iiL78rVKMkY5JVheIHysaQUoRR76KbTfyuGdW_2tSHNnVpU-_b1LSI3hytl36G4Y_kd30FEAcglSd_D_Fv9n9sfwLVGqqu</recordid><startdate>20240701</startdate><enddate>20240701</enddate><creator>Martinelli, Erika</creator><creator>Ciardiello, Davide</creator><creator>Martini, Giulia</creator><creator>Napolitano, Stefania</creator><creator>Del Tufo, Sara</creator><creator>D’Ambrosio, Luca</creator><creator>De Chiara, Marco</creator><creator>Famiglietti, Vincenzo</creator><creator>Nacca, Valeria</creator><creator>Cardone, Claudia</creator><creator>Avallone, Antonio</creator><creator>Cremolini, Chiara</creator><creator>Pietrantonio, Filippo</creator><creator>Maiello, Evaristo</creator><creator>Granata, Vincenza</creator><creator>Troiani, Teresa</creator><creator>Cappabianca, Salvatore</creator><creator>Ciardiello, Fortunato</creator><creator>Nardone, Valerio</creator><creator>Reginelli, Alfonso</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>4T-</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20240701</creationdate><title>Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial</title><author>Martinelli, Erika ; Ciardiello, Davide ; Martini, Giulia ; Napolitano, Stefania ; Del Tufo, Sara ; D’Ambrosio, Luca ; De Chiara, Marco ; Famiglietti, Vincenzo ; Nacca, Valeria ; Cardone, Claudia ; Avallone, Antonio ; Cremolini, Chiara ; Pietrantonio, Filippo ; Maiello, Evaristo ; Granata, Vincenza ; Troiani, Teresa ; Cappabianca, Salvatore ; Ciardiello, Fortunato ; Nardone, Valerio ; Reginelli, Alfonso</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-b29f2bdb4290b304591737aec5f726709da4d4c31dec8a3337d3e36f5eee82583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biomarkers</topic><topic>Cancer therapies</topic><topic>Cetuximab - administration & dosage</topic><topic>Cetuximab - therapeutic use</topic><topic>Colorectal cancer</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Datasets</topic><topic>Female</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Liver</topic><topic>Liver Neoplasms - diagnostic imaging</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - secondary</topic><topic>Male</topic><topic>Medical imaging</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Multivariate analysis</topic><topic>Oncology</topic><topic>Patients</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacotherapy</topic><topic>Progression-Free Survival</topic><topic>Radiomics</topic><topic>Regression analysis</topic><topic>Short Communication</topic><topic>Software</topic><topic>Tomography</topic><topic>Tomography, X-Ray Computed - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martinelli, Erika</creatorcontrib><creatorcontrib>Ciardiello, Davide</creatorcontrib><creatorcontrib>Martini, Giulia</creatorcontrib><creatorcontrib>Napolitano, Stefania</creatorcontrib><creatorcontrib>Del Tufo, Sara</creatorcontrib><creatorcontrib>D’Ambrosio, Luca</creatorcontrib><creatorcontrib>De Chiara, Marco</creatorcontrib><creatorcontrib>Famiglietti, Vincenzo</creatorcontrib><creatorcontrib>Nacca, Valeria</creatorcontrib><creatorcontrib>Cardone, Claudia</creatorcontrib><creatorcontrib>Avallone, Antonio</creatorcontrib><creatorcontrib>Cremolini, Chiara</creatorcontrib><creatorcontrib>Pietrantonio, Filippo</creatorcontrib><creatorcontrib>Maiello, Evaristo</creatorcontrib><creatorcontrib>Granata, Vincenza</creatorcontrib><creatorcontrib>Troiani, Teresa</creatorcontrib><creatorcontrib>Cappabianca, Salvatore</creatorcontrib><creatorcontrib>Ciardiello, Fortunato</creatorcontrib><creatorcontrib>Nardone, Valerio</creatorcontrib><creatorcontrib>Reginelli, Alfonso</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Docstoc</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical drug investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martinelli, Erika</au><au>Ciardiello, Davide</au><au>Martini, Giulia</au><au>Napolitano, Stefania</au><au>Del Tufo, Sara</au><au>D’Ambrosio, Luca</au><au>De Chiara, Marco</au><au>Famiglietti, Vincenzo</au><au>Nacca, Valeria</au><au>Cardone, Claudia</au><au>Avallone, Antonio</au><au>Cremolini, Chiara</au><au>Pietrantonio, Filippo</au><au>Maiello, Evaristo</au><au>Granata, Vincenza</au><au>Troiani, Teresa</au><au>Cappabianca, Salvatore</au><au>Ciardiello, Fortunato</au><au>Nardone, Valerio</au><au>Reginelli, Alfonso</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial</atitle><jtitle>Clinical drug investigation</jtitle><stitle>Clin Drug Investig</stitle><addtitle>Clin Drug Investig</addtitle><date>2024-07-01</date><risdate>2024</risdate><volume>44</volume><issue>7</issue><spage>541</spage><epage>548</epage><pages>541-548</pages><issn>1173-2563</issn><issn>1179-1918</issn><eissn>1179-1918</eissn><abstract>Background
CAVE is a single arm, Phase 2 trial, that demonstrated anti-tumor activity of cetuximab rechallenge plus avelumab in patients with
RAS
wild type (wt) metastatic colorectal cancer (mCRC).
Objective
We conducted a post hoc analysis to identify potential radiomic biomarkers for patients with CRC liver metastasis (LM).
Patients and Methods
Patients with LM that could be measured by enhanced contrast phase computed tomography (CT) imaging at baseline and at first response evaluation were included. Multiple texture parameters were extracted with the LifeX Software. Delta-texture (D-TA) variations were calculated by comparing data at baseline and after treatment.
Results
Overall, 55/77 patients (71%) had LM; 39 met the inclusion criteria for the current analysis. The D-TA parameters that significantly correlated at univariate analysis with median progression-free survival (mPFS) were Entropy
Histogram
(
p
= 0.021), Homogeneity
GLCM
(
p
< 0.001) and Dissimilarity
GLCM
(
p
= 0.002). At multivariate analysis, only Homogeneity
GLCM
resulted significant for PFS (
p
= 0.001). Patients (19/39, 48.7%) with reduction of Homogeneity
GLCM
experienced better mPFS (4.6 vs 2.9 months; HR 0.45; 95% CI 0.23–0.88;
p
= 0.021) and median overall survival (mOS) (17.3 vs 6.8 months; HR 0.40, 95% CI 0.21–0.80;
p
= 0.010). A trend to better mPFS, was also observed in patients with
RAS/BRAF
wt circulating tumor DNA and reduction of Homogeneity
GLCM
. Overall survival was significantly better in this subgroup of patients with low Homogeneity
GLCM
: mOS was 17.8 (95% CI 15.5–20.2) versus 6.8 months (95% CI 3.6–10.0) (HR 0.34, 95% CI 0.14–0.81;
p
= 0.016).
Conclusion
Reduction in the D-TA parameter Homogeneity
GLCM
by radiomic analysis correlates with improved outcomes in patients with LM receiving cetuximab rechallenge plus avelumab therapy. Larger prospective studies are needed to validate and confirm these findings.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>38886336</pmid><doi>10.1007/s40261-024-01372-0</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1173-2563 |
| ispartof | Clinical drug investigation, 2024-07, Vol.44 (7), p.541-548 |
| issn | 1173-2563 1179-1918 1179-1918 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3070793549 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers Cancer therapies Cetuximab - administration & dosage Cetuximab - therapeutic use Colorectal cancer Colorectal Neoplasms - drug therapy Colorectal Neoplasms - pathology Datasets Female Humans Internal Medicine Liver Liver Neoplasms - diagnostic imaging Liver Neoplasms - drug therapy Liver Neoplasms - secondary Male Medical imaging Medical prognosis Medicine Medicine & Public Health Metastasis Middle Aged Multivariate analysis Oncology Patients Pharmacology/Toxicology Pharmacotherapy Progression-Free Survival Radiomics Regression analysis Short Communication Software Tomography Tomography, X-Ray Computed - methods |
| title | Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T13%3A37%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radiomic%20Parameters%20for%20the%20Evaluation%20of%20Response%20to%20Treatment%20in%20Metastatic%20Colorectal%20Cancer%20Patients%20with%20Liver%20Metastasis:%20Findings%20from%20the%20CAVE-GOIM%20mCRC%20Phase%202%20Trial&rft.jtitle=Clinical%20drug%20investigation&rft.au=Martinelli,%20Erika&rft.date=2024-07-01&rft.volume=44&rft.issue=7&rft.spage=541&rft.epage=548&rft.pages=541-548&rft.issn=1173-2563&rft.eissn=1179-1918&rft_id=info:doi/10.1007/s40261-024-01372-0&rft_dat=%3Cproquest_cross%3E3086411415%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3086411415&rft_id=info:pmid/38886336&rfr_iscdi=true |